Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with ...

The Fracture Risk Assessment Tool predictions suggest patients who don’t meet guideline criteria for parathyroidectomy may ...

Semaglutide and tirzepatide use is rising among patients with rheumatic and musculoskeletal diseases and is linked to meaningful 1-year weight loss, especially in tirzepatide users.

Participants on weekly injections of 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, and 45.3% of participants achieved ≥ 30% weight loss.

Emerging evidence suggests some sugar substitutes may affect metabolism, gut microbiome, and cardiovascular health more than ...

The conditional authorization covers adults and children aged 2 years and older with severe or life-threatening ...

Pierre de Brémond d’Ars, a French GP who leads the evidence-based medicine group NoFakeMed, tells Medscape’s French edition ...

A cohort study of births in Brazil found increased hospitalization risk through age 3 after maternal chikungunya; results ...

NICE has recommended a new treatment option for adults with recurrent or metastatic cervical cancer that has progressed on or ...

Dr Sunnie Kim previews key GI trials highlighting novel bispecific antibodies, dual immunotherapy combinations, KIT ...

Higher dermatologist density is associated with lower proportions of late stage melanoma diagnosis across US health service ...